DDO-3055   Click here for help

GtoPdb Ligand ID: 12785

Synonyms: compound 17 [PMID: 32787144] | DDO3055
Compound class: Synthetic organic
Comment: DDO-3055 is an inhibitor of the prolyl hydroxylase PHD2 (egl-9 family hypoxia inducible factor 1; EGLN1) [1]. It increases the plasma erythropoietin level and alleviates anemia in vivo.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 108.22
Molecular weight 360.75
XLogP 1.34
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C(#CC1=CN=C(C(=C1)O)C(=O)NCC(=O)O)COC2=CC=C(C=C2)Cl
Isomeric SMILES OC1=CC(C#CCOC2=CC=C(Cl)C=C2)=CN=C1C(NCC(O)=O)=O
InChI InChI=1S/C17H13ClN2O5/c18-12-3-5-13(6-4-12)25-7-1-2-11-8-14(21)16(19-9-11)17(24)20-10-15(22)23/h3-6,8-9,21H,7,10H2,(H,20,24)(H,22,23)
InChI Key AIKDJELJHUPYNG-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
DDO-3055 is in clinical trial as a treatment for renal anemia where erythropoietin production is compromised by chronic kidney disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04470063 Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases. Phase 1 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT03976115 A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease Phase 1 Interventional Jiangsu HengRui Medicine Co., Ltd.